Autonomix Medical announced today that it completed the first three patient procedures in a proof-of-concept trial of its ablation technology.
The Woodlands, Texas-based Autonomix designed its transvascular radiofrequency (RF) ablation technology to treat pancreatic cancer pain.
Current approaches to treat this pain include opioids or ethanol injections. However, Autonomix says those approaches may only provide limited relief and may lead to risky side effects. The company hopes its tissue ablation technology opens the door to a “novel, blockbuster disease treatment.” In January, Autonomix completed an animal study, leading to this proof-of-concept effort.
The company designed its catheter-based technology to perform two tasks. First, it senses neural signals associated with pain or disease. Then, it precisely targets those nerves for treatment.
Autonomix set out to successfully ablate somatic nerves and mitigate pain in its proof-of-concept trial…